HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Whether Higher Sales Or Lower Volumes, Price Increases Make Presence Known For P&G And C&D

Executive Summary

Both health, wellness and beauty product marketers on report increased prices helped drive revenue growth during April-June period while also factoring in lower sales volumes.

You may also be interested in...

P&G Prepares For Growth To Move From Price Increases To Volume As It Girds For FX Headwind

Contribution of price increases to P&G’s organic sales growth will decrease 3 to 4 points during its FY2024 while volume will “progress sequentially,” says CFO Andre Schulten during firm’s first-quarter earnings briefing. Net sales up 6% to $21.9bn in July-September.

US Q3 Consumer Health Earnings Preview: Phenylephrine Question Punctuates Quarter

Consumer health products sector’s earnings reports for July-September period are its first since FDA advisory committee unanimously voted that results of research agency presented show oral phenylephrine at OTC monograph doses is ineffective to treat nasal congestion.

P&G Exploring AI-Based Manufacturing, Shelf Optimization With Retailers: ‘Supply Chain 3.0’ Update

Automation through artificial intelligence, which saw significant progress during the COVID-19 pandemic amid labor shortages, is an area of focus for P&G as it continues work under its Supply Chain 3.0 initiative. The firm also is providing data analysis to retailers to encourage shelf simplification, company leadership says.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts